Bioelectrix has been selected for the CO-AX Accelerator at Sahlgrenska Science Park, joining a cohort of health innovators shaping the next generation of healthcare solutions. As part of the program, Bioelectrix will accelerate the development of our bioelectronic wound care solution—designed to support treatment of hard-to-heal wounds through biocompatible electrostimulation and real-time monitoring.
CO-AX recently introduced the new cohort publicly, highlighting Bioelectrix’s work and our collaboration through co-incubation with Chalmers Ventures.
Why CO-AX matters for Bioelectrix
CO-AX exists to support and accelerate companies tackling major health challenges. Being part of the accelerator gives Bioelectrix access to an ecosystem built for scaling healthcare innovation—combining sector expertise, partners, and networks that strengthen both our technology and our go-to-market journey.
For Bioelectrix, this means:
- More competence and capability around scaling in healthcare — stronger sparring on regulatory, clinical pathways, reimbursement logic, and implementation.
- Sharper product development — support that helps us validate, refine, and prioritize what creates the most clinical and commercial value.
- Expanded network and partnerships — closer access to industry contacts, clinical environments, and innovation leaders across the Nordics and beyond.
- Increased visibility and credibility — being part of a respected accelerator helps attract collaborators, customers, and future funding.
Building better solutions for hard-to-heal wounds
Hard-to-heal wounds place a heavy burden on patients, caregivers, and healthcare systems. Bioelectrix is developing a solution that combines electrostimulation with monitoring to support improved healing outcomes and more informed care decisions. Our goal is to help healthcare providers treat patients more effectively while supporting better resource use.
Part of a strong cohort of healthcare innovators
The CO-AX cohort brings together companies across multiple domains—therapeutics, diagnostics, clinical trial recruitment, AI for clinical workflows, and novel non-invasive treatments—creating a valuable environment for cross-learning and collaboration.
Looking ahead
We’re excited to contribute to the CO-AX community and to build momentum throughout 2026. We’ll share more updates as we progress through the program—covering milestones, partnerships, and development steps.
Want to learn more or explore collaboration?
Contact us at or follow Bioelectrix on LinkedIn for updates.
